background
felin
infecti
periton
fip
lethal
immunemedi
diseas
caus
felin
coronaviru
fcov
current
therapi
proven
efficaci
avail
search
agent
may
prove
clinic
effect
fcov
infect
five
analog
overlap
peptid
design
synthes
base
put
heptad
repeat
sequenc
spike
protein
fcov
antivir
efficaci
evalu
method
plaqu
reduct
assay
mtt
bromid
cytotox
assay
perform
studi
peptid
select
use
plaqu
reduct
assay
inhibit
felin
coronaviru
infect
result
demonstr
peptid
concentr
inhibit
viral
replic
peptid
exhibit
effect
antivir
effect
combin
known
antivir
agent
human
signific
synergist
antivir
effect
observ
data
suggest
synthet
peptid
could
serv
valuabl
addit
current
fip
prevent
method
felin
coronaviru
fcov
group
coronaviru
usual
caus
mild
gastrointestin
symptom
cat
howev
small
percentag
seroposit
anim
develop
highli
lethal
felin
infecti
periton
fip
neither
effect
vaccin
effect
drug
current
avail
prevent
control
diseas
interferon
ifn
immun
inhibitor
immun
modul
support
therapi
use
clinic
efficaci
typic
poor
sinc
pandem
sever
acut
respiratori
syndrom
sar
numer
antivir
drug
develop
control
sar
coronaviru
sarscov
includ
protein
heptad
repeat
hr
peptid
carbohydratebind
agent
cathepsin
inhibitor
hiv
proteas
inhibitor
nitric
oxid
sirna
interferon
except
protein
hr
peptid
abovement
reagent
test
abil
inhibit
fcov
replic
eg
cathepsin
l
cathepsin
b
inhibitor
inhibit
entri
pyridin
noxid
deriv
found
inhibitori
coronavirus
particular
felin
coronaviru
type
ii
strain
fipv
protein
fcov
consist
subunit
locat
nterminu
molecul
spheric
structur
includ
domain
bind
receptor
host
cell
locat
cterminu
spike
protein
contain
primari
region
respons
fusion
viru
cell
membran
host
upon
bind
host
receptor
undergo
structur
transform
expos
form
sixhelix
bundl
structur
type
helix
structur
format
characterist
class
viral
fusion
mani
vitro
studi
sarscov
report
exogen
peptid
bind
viral
therebi
effici
block
entri
viru
cell
inhibit
replic
viru
multipl
agent
target
differ
stage
viral
replic
success
use
control
infect
human
human
immunodefici
viru
hiv
human
hepat
c
viru
hcv
regard
fcov
infect
previou
vitro
studi
demonstr
combin
nelfinavir
galanthu
nivali
agglutinin
gna
synergist
antivir
effect
inhibit
fcov
replic
order
find
less
expens
effect
antivir
combin
improv
prognosi
cat
fip
peptid
base
put
protein
design
test
inhibitori
effect
possibl
synerg
peptid
known
antifcov
agent
investig
feli
catu
whole
cell
kindli
provid
professor
peter
j
rottier
utrecht
univers
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
iuml
penicillin
streptomycin
co
type
ii
strain
viru
isol
local
sequenc
fcov
protein
hr
peptid
fcov
hr
peptid
design
base
protein
type
ii
fcov
genbank
access
peptid
dissolv
aqueou
naoh
ph
aqueou
naoh
prepar
dubl
distil
water
adjust
ph
n
naoh
peptid
sequenc
shown
figur
determin
cytotox
peptid
cell
cellsml
grown
plate
h
cell
preincub
without
differ
concentr
peptid
triplic
h
assess
mtt
bromid
assay
briefli
cell
well
incub
mtt
reagent
mgml
h
cell
lyse
lysi
buffer
sd
dimethyl
formamid
adjust
ph
glacial
acid
remov
mtt
absorb
valu
nm
measur
microelisa
reader
cell
viabil
rel
absorb
nm
sampl
peptid
rel
absorb
sampl
without
peptid
effect
peptid
select
use
plaqu
reduct
assay
cell
cellsml
seed
plate
incub
h
prior
use
variou
concentr
peptid
incub
multipl
infect
moi
incub
h
mixtur
peptid
viru
incub
cell
h
supernat
remov
dmem
contain
fb
ad
well
supernat
collect
h
postinfect
incub
cell
h
incub
supernat
remov
dmem
contain
fb
ad
cell
fix
stain
h
postinfect
extent
cytopath
effect
cpe
assess
base
result
fifti
percent
inhibitori
concentr
ic
calcul
use
interpol
method
fcov
hr
peptid
combin
human
interferonalpha
roch
preincub
cell
cultur
dmem
contain
fb
h
supernat
remov
cell
infect
moi
supernat
remov
h
incub
peptid
select
concentr
incub
cell
dmem
contain
fb
supernat
collect
h
incub
titrat
viral
titer
presenc
combin
determin
use
plaqu
reduct
assay
previous
describ
sampl
analyz
triplic
statist
analys
synerg
antivir
activ
perform
use
twoway
analysi
varianc
assess
toxic
five
fcov
peptid
design
studi
six
concentr
peptid
rang
use
treat
cell
h
viabil
cell
evalu
test
concentr
cell
surviv
rate
greater
indic
peptid
toxic
host
cell
cc
valu
base
cell
viabil
result
three
concentr
peptid
ie
chosen
test
peptid
antivir
effect
result
show
among
five
peptid
could
significantli
reduc
viral
titer
reduct
respect
figur
inhibit
concentr
depend
compar
untreat
group
tabl
p
figur
ic
valu
respect
tabl
potent
inhibitor
fcov
replic
among
test
peptid
human
recommend
therapi
fip
howev
use
alon
complet
control
viral
replic
cat
determin
whether
effect
inhibitor
among
fcov
hr
peptid
could
increas
antivir
activ
combin
human
inhibit
assay
perform
figur
result
show
high
concentr
iu
use
alon
viral
titer
reduc
logpfuml
respect
growth
fcov
could
block
complet
howev
combin
iu
combin
iu
complet
inhibitori
effect
observ
viral
titer
reduc
logpfuml
inhibitori
effect
higher
addit
effect
mediat
two
agent
alon
figur
combin
show
synerget
effect
determin
twoway
analysi
varianc
p
util
hr
peptid
deriv
spike
protein
interfer
fusion
viral
envelop
host
membran
thu
inhibit
viral
replic
wellknown
success
inhibit
infect
numer
virus
class
fusion
protein
among
peptid
peptid
enfuvirtid
alreadi
incorpor
clinic
regimen
shown
strong
efficaci
hiv
infect
although
crystal
structur
protein
fcov
remain
determin
align
amino
acid
sequenc
deriv
fcov
member
coronavirus
domain
predict
peptid
correspond
domain
design
chosen
found
effect
previou
studi
report
sever
peptid
deriv
domain
abl
inhibit
sarscov
infect
ic
less
inhibitori
efficaci
correl
length
report
peptid
central
helix
region
contain
amino
acid
residu
critic
inhibit
sarscov
infect
addit
truncat
ntermin
found
relat
loss
potenc
ctermin
exam
inhibitori
effect
felin
peptid
found
extra
residur
nntlvnl
cterminu
compar
show
signific
potenti
inhibit
viral
replic
figur
find
indic
residu
might
play
import
role
process
membran
fusion
thu
inhibit
viral
replic
human
report
antifcov
effect
inhibit
viral
replic
synergist
effect
found
combin
ribavirin
howev
due
sever
advers
reaction
ribavirin
drug
feasibl
clinic
use
present
studi
found
combin
nontox
peptid
human
exhibit
satisfactori
synergist
antivir
effect
unit
combin
result
complet
inhibit
one
antivir
peptid
current
use
hiv
treatment
enfuvirtid
shown
caus
pain
discomfort
inject
site
reaction
includ
tuber
nodul
erythematosu
diarrhea
regurgit
pruritu
report
hr
peptid
fcov
must
test
followup
clinic
studi
determin
whether
advers
effect
felin
fip
immunemedi
diseas
addit
antivir
drug
control
viral
replic
treatment
diseas
also
requir
ifn
immun
inhibitor
cytokin
antagonist
achiev
better
prognosi
studi
util
vitro
experi
demonstr
hr
peptid
inhibit
fcov
replic
furthermor
peptid
combin
human
lower
dose
agent
need
achiev
complet
inhibit
viral
replic
result
suggest
combin
use
two
drug
togeth
appropri
agent
modifi
immun
function
potenti
therapi
treatment
fip
demonstr
studi
synthet
peptid
could
inhibit
viral
replic
peptid
exhibit
signific
synergist
antivir
effect
combin
data
suggest
combin
two
agent
could
conceiv
design
experi
ijl
llc
perform
experi
ijl
wtt
analyz
data
ij
wtt
leh
contribut
reagentsmaterialsanalysi
tool
ijl
llc
wrote
manuscript
ilj
wtt
llc
